ArticleFrontiers in cardiovascular medicine2026
Association of age at menopause with cardiovascular disease and mortality:insights from NHANES and a clinical cohort.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Age at menopause is closely associated with cardiovascular disease and mortality, whereas the underlying mechanisms remain unclear. This study employed mediation analysis to explore potential pathways underlying this association. Methods: Natural postmenopausal women were identified from the NHANES database to assess the association between age at menopause and cardiovascular disease and mortality. Mediation analysis was performed to identify potential mediators. A hospital-based cohort was used for a supportive analysis. Results: Compared with women with menopause at 50-51 years, those with menopause before 40 years had a higher prevalence of cardiovascular disease and increased risks of all-cause and cardiovascular mortality. Dose-response analysis indicated that each one-year decrease in age at menopause was associated with 3%, 3%, and 4% increases in cardiovascular disease prevalence, all-cause mortality, and cardiovascular mortality, respectively. Mediation analysis showed that total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), hypertension, and glycated hemoglobin partially mediated the association between age at menopause and adverse outcomes. A hospital-based cohort study further supported these findings. Conclusion: Early menopause is significantly associated with higher cardiovascular disease prevalence, all-cause mortality, and cardiovascular mortality, and this association is partially mediated by metabolic dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.